SkQ

Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%

Retrieved on: 
Wednesday, August 16, 2023
Ranibizumab, Therapy, Czech Republic, SkQ, CMC, COVID-19, Clinical trial, Therapeutic Goods Administration, Research, Diabetic retinopathy, Trial of the century, Chemistry, Bevacizumab, Telecanthus, Hospital, Traction, Trust, Acquisition, Patent, Investment, Patient, VISTA, European Medicines Agency, Macular edema, Growth, City, Conditional sentence, FDA, NMPA, US FDA, Disease, Safety, D, Pharmaceutical industry, PRC, Ophthalmology

HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").

Key Points: 
  • HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
  • The profit of the Group increased by 22.0% to approximately HK$170 million as compared to approximately HK$139.2 million for the same period last year.
  • As of 30 June 2023, the Group had cash and cash equivalents of approximately HK$506 million (31 December 2022: approximately HK$543 million).
  • The Group's revenue is primarily made up of the segments of Ophthalmology and Surgical (wound care and healing).

Essex Bio-Technology Announces 2022 Annual Financial Results

Retrieved on: 
Wednesday, March 8, 2023
City, Traction, Conditional sentence, US FDA, COVID-19, VISTA, Clinical trial, Patent, NMPA, Acquisition, Eye, Hospital, Diabetic retinopathy, Trial of the century, CMC, European Medicines Agency, Growth, Anti-VEGF, Policy, Intellectual property, Research, Chemistry, Granule, Macular edema, Telecanthus, Patient, Invention, FDA, SkQ, Marketing, DNA, Best, Bevacizumab, D, TRIPS Agreement, Trust, Czech Republic, Ranibizumab, Therapeutic Goods Administration, Disease, Wound healing, Therapy, Cryptocurrency, Pharmaceutical industry, Property management, Vaccine, Ophthalmology, PRC, Surgery

HONG KONG, Mar 8, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.

Key Points: 
  • HONG KONG, Mar 8, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.
  • As of the date of the results announcement, the clinical operations of hospitals and outpatient clinics progressively resumed to normalcy.
  • As of 31 December 2022, the Group had cash and cash equivalents of approximately HK$544 million (2021: approximately HK$671 million).
  • Together with the interim dividend of HK$ 0.04 per ordinary share paid on 21 September 2022, the total dividend for 2022 would be HK$ 0.065 (2021: HK$ 0.095) per ordinary share.

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

Retrieved on: 
Thursday, October 13, 2022
Vance DeGeneres, Neurodegeneration, Anti-inflammatory, Hospital, Inflammation, Invention, VISTA, DED, Agreement, Eye, Glaucoma, Trial of the century, Product, Company, Leber's hereditary optic neuropathy, LHON, The Group, Mitochondrion, Group, Board, Duane syndrome, Patent, Oxidative stress, FDA, TRIPS Agreement, AMD, Pharmaceutical industry, Ophthalmology, SkQ, Dermatology

Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.

Key Points: 
  • Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.
  • The core technology behind Mitotech products is based on a novel class of small molecules - mitochondria targeting cardiolipin peroxidation inhibitors.
  • Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
  • Additionally, glaucoma, Leber's Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis programmes for SkQ1 ophthalmic solution are at pre-clinical stage.

Essex Bio-Technology Announces 2021 Financial Results

Retrieved on: 
Tuesday, March 22, 2022
Conditional sentence, Hospital, SkQ, NMPA, US, Exudate, VISTA, Therapeutic Goods Administration, Trust, Trial of the century, Association of British HealthTech Industries, Cornea, Science, The Group, Therapy, DNA, Patent, Investment, Growth, Clinical trial, European Medicines Agency, Board, Board on Science, Technology, and Economic Policy, Review, Duane syndrome, COVID, Patient, IP, Company, Growth factor, Leadership, Group, Granule, City, US FDA, Oxidative stress, Czech Republic, MAH, COVID-19, Traction, Bevacizumab, Acquisition, Property management, Vaccine, Pharmaceutical industry, Television, Animal, Cosmetics, Renewable energy, Surgery, Dermatology, PRC, Ophthalmology

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Key Points: 
  • HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.
  • Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties.
  • Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges.
  • The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021.